Details for New Drug Application (NDA): 206286
✉ Email this page to a colleague
NDA 206286 describes TADALAFIL, which is a drug marketed by Accord Hlthcare, Ajanta Pharma Ltd, Alembic, Amneal Pharms Co, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Dr Reddys, Fourrts Labs, Hangzhou Binjiang, Hetero Labs Ltd Iii, Lupin Ltd, Macleods Pharms Ltd, Norvium Bioscience, Novitium Pharma, Prinston Inc, Qilu Pharm Hainan, Rising, Shandong, Sun Pharm, Sunshine, Teva Pharms Usa, Torrent, Umedica, Unichem, Vkt Pharma, Watson Labs Inc, and Zydus Pharms, and is included in forty NDAs. It is available from forty-three suppliers. Additional details are available on the TADALAFIL profile page.
The generic ingredient in TADALAFIL is tadalafil. There are twenty-five drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
The generic ingredient in TADALAFIL is tadalafil. There are twenty-five drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
Summary for 206286
| Tradename: | TADALAFIL |
| Applicant: | Aurobindo Pharma Ltd |
| Ingredient: | tadalafil |
| Patents: | 0 |
Pharmacology for NDA: 206286
| Mechanism of Action | Phosphodiesterase 5 Inhibitors |
Medical Subject Heading (MeSH) Categories for 206286
Suppliers and Packaging for NDA: 206286
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TADALAFIL | tadalafil | TABLET;ORAL | 206286 | ANDA | Aurobindo Pharma Limited | 65862-880 | 65862-880-60 | 60 TABLET in 1 BOTTLE (65862-880-60) |
| TADALAFIL | tadalafil | TABLET;ORAL | 206286 | ANDA | Northwind Pharmaceuticals, LLC | 82868-028 | 82868-028-06 | 6 TABLET in 1 BOTTLE, PLASTIC (82868-028-06) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
| Approval Date: | Feb 5, 2019 | TE: | AB2 | RLD: | No | ||||
Complete Access Available with Subscription
